StandardPlus : Tailored Immune Profiling with Your Specific Marker
Customize Teiko’s 41-marker CyTOF panel for peripheral blood mononuclear cell (PBMC) profiling with an additional antibody to track specific cell types, pathways, or targets
With StandardPlus, customers can add an additional antibody to Teiko’s Standard 41-marker PBMC panel to track a specific cell type, pathway, or target.
Customers will select a monoclonal antibody and Teiko will verify the staining of your marker of interest and its compatibility with the Standard PBMC CyTOF Panel.
Customers will receive a marker verification report, including a 6-point titration of the selected antibody, sample and gating quality control (QC) report for each cohort of processed samples, and Base, Core, or Premier analysis and deliverables accessible through Teiko’s web application.
CLIA-Validated PBMC CyTOF Backbone Panel Ready for Custom Antibody Addition
Integrate your specific antibody into a robust 41-marker backbone for accurate detection of immune cell types, subsets, and protein expressionDiscover immune biomarkers and features to understand dose escalation, uncover mechanisms of action, and complement pharmacodynamic assays in your clinical trials.
Add your cell type or marker of interest with our 41-marker CyTOF panel to analyze 800+ immune cell types and subsets. Ensure accurate cell frequency measurements with a coefficient of variation below 10% for all major immune cell types with the 41-marker backbone.
Total Average Coefficient of Variations:
- Intra-Run Precision: 3.52%
- Inter-Run Precision: 6.66%
- Inter-Operator Precision:
- Donor 1: 4.83%
- Donor 2: 7.36%
Validated with cryopreserved human PBMC from three healthy donors.
Up to 800+ Immune Subsets and States Analyzed
Expertly Designed Human Pan-Immune PBMC Panel
The TokuProfile Standard Human Pan-Immune PBMC panel includes:
- Markers to identify every major immune cell population and subsets
- Expression of key co-stimulatory and co-inhibitory molecules that regulate cell function
- Markers of recent activation and effector function
-
T cells
- CD3
- Total T cells
- CD4
- CD4+ T cells
- CD8a
- CD8+ T cells
- CD27
- Maturation
- CD45RA
- Naive/Memory
- CCR7 (CD197)
- Naive/Memory
- Foxp3
- Treg
- CD25
- Treg, activation
- CD127
- T cell subsets
- T-bet
- T cell subsets
- CD38
- Maturation
- CD69
- Early Activation
- HLA-DR
- Activation
- CD56
- NKT, T cell subsets
- gdTCR
- gdT cells
- CTLA-4 (CD152)
- Checkpoint
- PD-1
- Checkpoint
- TIM-3
- Checkpoint
- TIGIT
- Checkpoint
- LAG3
- Checkpoint
- CD57
- Senescence
- KLRG-1
- Senescence
- Granzyme B
- Effector
- CD95
- Stem cell memory
- CD39
- Tumor specific
- CD28
- Co-stimulation, Maturation
- CD161
- Inhibitory Receptor
- ICOS
- Checkpoint
-
B cells
- CD19
- Total B cells
- CD25
- Activation
- CD27
- Naive/Memory
- CD38
- Naive/Memory
- HLA-DR
- Antigen presentation
-
NK cells
- CD56
- NK cell subsets
- CD16
- NK cell subsets
- CD8a
- NK cell subsets
- CD38
- Activation
- T-bet
- Maturation
- Granzyme B
- Effector
-
Myeloid cells
- CD11b
- Monocytes, macrophages
- CD11c
- Monocytes, macrophages, DCs
- CD14
- Monocyte subsets, Macrophages
- CD16
- Monocyte subsets
- CD33
- Total myeloid
- CD123
- pDC
- PD-L1
- Checkpoint ligand
- HLA-DR
- Antigen presentation
- LOX-1
- PMN-MDSCs
-
Granulocytes
Whole blood only- CD66b
- Granulocytes
- CD11b
- Neutrophils
- CD16
- Neutrophils
- CD15
- Neutrophils
- CD123
- Basophils
-
General
- CD45
- Total immune cells
- KI67
- Proliferation
- DNA
- Singlets
- Live/Dead
- Viability
- IgG4
- Nivo/Pembro
CLIA Validation Data
Mass Cytometry Assay for Pan-Immune Profiling of PBMCsFill out the form below to access our CLIA Validation plan, report, and data and SOPs.